natgillin/translations-raw huggingface dataset:
3 pre-filled syringes + 3 alcohol swabs
3 napunjene štrcaljke + 3 maramice natopljene alkoholom
3 Pre-filled syringes with 1.2 ml solvent: sodium chloride solution, 5.4 mg/ml, 3 Vial adapters with needles + 6 alcohol wipes
3 napunjene štrcaljke s 1,2 ml otapala: otopina natrijevog klorida 5,4 mg/ml, 3 nnastavka za bočicu s iglom + 6 tupfera natopljenih alkoholom
3 pre-filled syringes with solvent for the Betaferon powder (sodium chloride solution 5.4 mg/ml (0.54% w/v))
3 napunjene štrcaljke s otapalom za Betaferon prašak (otopina natrijevog klorida (5,4 mg/ml (0,54 % m/V))),
3 pre-filled syringes with solvent for the Betaferon powder (sodium chloride solution 5.4 mg/ml (0.54% w/v))
3 napunjene štrcaljke s otapalom za Betaferon prašak (otopina natrijevog klorida od 5,4 mg/ml (0,54 % m/V)),
3 pre-filled syringes.
3 napunjene štrcaljke.
3 Primary analysis for double blind period
3 Primarna analiza za dvostruko slijepo razdoblje
3 produced in yeast (Saccharomyces cerevisiae) by recombinant DNA technology
3 Proizveden tehnologijom rekombinantne DNK u stanicama kvasca (Saccharomyces cerevisiae)
3 produced in yeast (Saccharomyces cerevisiae) cells by recombinant DNA technology
3 Proizveden tehnologijom rekombinantne DNK u stanicama kvasca (Saccharomyces cerevisiae)
3 Some of these pathogens (e.g.
3 Neki od tih patogena (npr.
3 Spontaneous reports data (unknown denominator)
3 Podaci iz spontanih prijava (nepoznati nazivnik)
3 spot-on applicators
3 aplikatora za nakapavanje
3 Study C08-003: 8 patients received ESA which was discontinued in 3 of them during eculizumab therapy
3Ispitivanje C08-003: 8 bolesnika primilo je sredstvo koje stimulira eritropoezu, čija je primjena obustavljena u njih 3 za vrijeme terapije ekulizumabom.
3 tablets 6 tablets
3 tablete 6 tableta
3 tablets in the morning and 3 tablets in the evening
3 tablete ujutro i 3 tablete navečer
3 tablets in the morning and 4 tablets in the evening
3 tablete ujutro i 4 tablete navečer
3 tablets MIRAPEXIN
3 tablete MIRAPEXIN
3 tablets of INCIVO twice daily (morning and evening) with food.
3 tablete INCIVA dva puta na dan (ujutro i navečer) uz hranu.
3 There was no statistically significant difference compared to placebo.
3Nije bilo statistički značajne razlike u odnosu na placebo.
3 This adverse reaction was identified through post-marketing surveillance but not observed in randomised controlled clinical studies in adults or paediatric HIV clinical studies for emtricitabine or in randomised controlled clinical studies or the tenofovir disoproxil expanded access program for tenofovir disoproxil.
3 Ova je nuspojava prepoznata tijekom praćenja nakon stavljanja lijeka u promet, ali nije opažena u randomiziranim kontroliranim kliničkim ispitivanjima emtricitabina u odraslih ili kliničkim ispitivanjima emtricitabina u pedijatrijskih bolesnika zaraženih HIV-om niti u randomiziranim kontroliranim ispitivanjima tenofovirdizoproksila odnosno u programu proširenog pristupa terapiji tenofovirdizoproksilom.
3 This adverse reaction was identified through post-marketing surveillance but not observed in randomised controlled clinical studies in adults or paediatric HIV clinical studies for emtricitabine or in randomised controlled clinical studies or the tenofovir disoproxil fumarate expanded access program for tenofovir disoproxil fumarate.
3 Ova nuspojava prepoznata je tijekom praćenja lijeka nakon stavljanja u promet, ali nije opažena u randomiziranim kontroliranim kliničkim ispitivanjima emtricitabina u odraslih ili u kliničkim ispitivanjima emtricitabina u pedijatrijskih pacijenata zaraženih HIV-om ili u randomiziranim kontroliranim ispitivanjima tenofovirdizoproksilfumarata ili programu proširenog pristupa terapiji tenofovirdizoproksilfumaratom.
3 This adverse reaction was identified through post-marketing surveillance for emtricitabine but was not observed in randomised controlled clinical studies in adults or paediatric HIV clinical studies of emtricitabine.
3 Ova nuspojava prepoznata je tijekom praćenja emtricitabina nakon stavljanja u promet, ali nije bila opaţena u randomiziranim kontroliranim kliničkim ispitivanjima emtricitabina u odraslih ili u kliničkim ispitivanjima emtricitabina u pedijatrijskih bolesnika zaraţenih HIV-om.
3 This adverse reaction was identified through post-marketing surveillance for emtricitabine but was not observed in randomised controlled clinical studies in adults or paediatric HIV clinical studies of emtricitabine.
3 Ova nuspojava prepoznata je tijekom praćenja lijeka nakon stavljanja u promet, ali nije bila opažena u randomiziranim kontroliranim kliničkim ispitivanjima emtricitabina u odraslih ili u kliničkim ispitivanjima emtricitabina u pedijatrijskih bolesnika zaraženih HIV-om.
3 times daily + etravirine
3 puta dnevno +
3 to 23 months
3 do 23 mjeseca
3 to 36 months
3-36 mjeseci
3 to 36 months (N=17)
3-36 mjeseci
3 to 36 months (N=18)
3-36 mjeseci
3 to 4 % of patients may experience reactions at the injection site (such as reddening, unusually intense pain on injection, itching, hives, swelling or inflammation).
U 3 do 4% bolesnika mogu se pojaviti reakcije na mjestu injekcije (kao što su crvenilo, neuobičajeno jaka bol prilikom injiciranja, svrbež, koprivnjača, oticanje ili upala).
3 to 6 months hospital setting
od 3 do 6 mjeseci
3 to 8
3 do 8
3 to 8 years
47,1
3 to 8 years N = 51 N = 47
3 do 8 godina N = 51 N = 47
3 to <18 years
3 do <18 godina
3 To be used in combination with an antibacterial agent active against Gram-positive pathogens when these are known or suspected to be contributing to the infectious process
3 Kada je potvrđeno ili se sumnja da Gram-pozitivni patogeni pridonose razvoju infekcije, primjenjivati u kombinaciji s antibakterijskim lijekovima koji djeluju na Gram-pozitivne organizme
3 to less than 20 kg
od 3 do manje od 20 kg
3 to less than 4
od 3 do manje od 4
3 tubes
3 tube
3 vial + 3 vials
3 bočice + 3 bočice
3 vial adapters with a pre-attached needle
3 nastavka za bočicu s prethodno pričvršćenom iglom,
3 Vial adapters with needles + 6 alcohol wipes
3 nastavka za bočicu s iglom + 6 tupfera natopljenih alkoholom
3 VIALS
3 BOČICE
3 vials
3 bočica
3 Vulvovaginitis, balanitis and related genital infection include the following preferred terms: vulvovaginal mycotic infection, balanoposthitis, genital infection fungal, vaginal infection, and vulvovaginitis.
3 Vulvovaginitis, balanitis i srodne genitalne infekcije uključuju sljedeće preferirane pojmove: vulvovaginalna gljivična infekcija, balanopostitis, gljivična genitalna infekcija, vaginalna infekcija i vulvovaginitis.
3 VWD where maintenance of adequate levels may require greater doses than in other types of VWD.
3 von Willebrandove bolesti, gdje odgovarajuća razina može zahtijevati veće doze nego u drugim tipovima te bolesti.
3 Week 19-40: treat-to-target regimen for insulin dose adjustment to achieve pre-defined glucose target levels (pre-prandial <100 mg/dl (5.5 mmol/l), post-prandial <140 mg/dl (7.8 mmol/l)
3 19. - 40. tjedan režima liječenja usmjerenog ka cilju (engl. treat-to-target) za prilagođavanje doze inzulina kako bi se postigle prethodno definirane ciljne razine glukoze u krvi ( < 100 mg/dl (5,5 mmol/l) preprandijalno, < 140 mg/dl (7,8 mmol/l) postprandijalno)
3 weeks
3 tjedna
3 weeks after completion of the primary course for CPiV and
3 tjedna nakon osnovnog cijepljenja (primovakcinacija) za CPiV i
3 weeks after completion of the primary course for CPiV and
3 tjedna nakon završetka osnovnog cijepljenja za CPiV i
3 weeks after completion of the primary course for CPiV.
3 tjedna nakon završetka osnovnog cijepljenja za CPiV
3 weeks after completion of the primary course for CPiV.
3 tjedna nakon završetka osnovnog cijepljenja za CPiV.
3 weeks after initial treatment
3 tjedna nakon početnog liječenja
3 weeks after the first vaccination for CDV, CAV, CPV,
3 tjedna nakon prvog cijepljenja za CDV, CAV, CPV,
3 weeks after the first vaccination for CDV, CAV, CPV, and
3 tjedna nakon prvog cijepljenja za CDV, CAV, CPV, i
3 weeks after the first vaccination for CDV, CAV, CPV.
3 tjedna nakon prvog cijepljenja za CDV, CAV, CPV,
3 weeks n=180
3 tjedna n=180
3 weeks n=181
3 tjedna n=181
3 weeks n=277
3 tjedna n=277
3 weeks n=278
3 tjedna n=278
3 When clinical information on the patients was available to make a judgement, approximately 50% of the cases occurred in patients with pre-existing renal impairment, or in those receiving concomitant medicinal products known to cause rhabdomyolysis.
3 U bolesnika kod kojih su bili dostupni klinički podaci za prosudbu, u otprilike 50% slučajeva rabdomioliza se javila u bolesnika s ranije prisutnim oštećenjem bubrega, ili u onih koji su istodobno primali lijekove za koje je poznato da izazivaju rabdomiolizu.
3 Whole body region of interest
3 Područje cijelog tijela od interesa
3 x (30 capsules +
3 x (30 kapsula +
3 x 1 dose (0.5 ml)
3 x 1 doza (0,5 ml)
3 x 1 vial +
3 x 1 bočica +
3 x 100 mg twice daily
3 x 100 mg dvaput na dan
3 x 2.5 mL.
3 x 2,5 ml.
3 x 25 mg twice daily
3 x 25 mg dvaput na dan
3 x 30 dose inhaler
3 x 30–dozni inhaler
3 x 30 doses
3 x 30 doza
3 x 30 tablets
3 x 30 tableta
3 x 320 mg / 40 mg tablets
3 x 320 mg / 40 mg tablete
3 x/week dosing
doziranje 3 x tjedno
3 year CSR Q1 2019
3 godine CSR Q1 2019
3 years
godine
3 years -
3 godine
3 years After suspension
3 godine Nakon pripreme suspenzije
3 years at 2 °C – 8 °C.
3 godine na temperaturi 2°C–8°C.
3 years when stored in a freezer ( -20˚C ±5°C).
3 godine kada se čuva u zamrzivaču (-20˚C ±5°C).
3 years, as packaged for sale.
U originalnom pakiranju 3 godine.
3 years.
godine
3 years.
godine.
3 – 4 days or more until pain and acute
3-4 dana ili dulje do prestanka boli
3 – 8 years
3 – 8 godina
3% aluminium hydroxide gel expressed as mg Al3+ 1 mg
3% aluminij hidroksid gel (izraženo u mg Al3+): 1 mg
3% of patients (18/681) developed persistent antibodies to the PEG moiety of peginterferon beta-1a.
3% bolesnika (18/681) razvilo je perzistentna protutijela na PEG skupinu u peginterferonu beta-1a.
3% of patients exposed to Taltz had a shift from a normal baseline platelet value to <150,000 platelet cells/mm3 to ≥75,000 cells/mm3.
U 3% bolesnika izloženih lijeku Taltz došlo je do promjene broja trombocita od početne normalne vrijednosti na < 150 000 stanica/mm3 do ≥ 75 000 stanica/mm3.
3+1 schedule
raspored 3+1
3, 4 months
3, 4 mjeseca
3, 5 months
3, 5 mjeseca
3, 6 or 12 months N=1,718
3, 6 ili 12 mjeseci N=1718
3, 6 or 12 months N=1,731
3, 6 ili 12 mjeseci N=1731
3, 6 or 12 months N=2,419
3, 6 ili 12 mjeseci N=2419
3, 6 or 12 months N=4,131
3, 6 ili 12 mjeseci N=4131
3, 6 or 12 months N=4,150
3, 6 ili 12 mjeseci N=4150
3, 89079 Ulm Germany
3, 89079 Ulm Njemačka
3, dark peach opaque cap and dark peach opaque body, hard-shell gelatin capsule filled with white to off-white powder.
3 s tamnoružičastom neprozirnom kapicom i tamnoružičastim neprozirnim tijelom napunjena bjeličastim prahom.
3, dark peach opaque cap and white opaque body, hard-shell gelatin capsule filled with white to off-white powder.
3 s tamnoružičastom neprozirnom kapicom i bijelim neprozirnim tijelom napunjena bjeličastim prahom.
3, LT-35169, Panevėžys
3, LT-35169, Panevėžys,
3,000 IU/0.3 ml
3000 IU/0,3 ml
3,000 mg/day
3000 mg/dan
3,076.4 patient years.
3076,4 bolesničkih godina.
3,200 units*
3200 jedinica
3,200 units*,
3200 jedinica*,
3,4,5 months
3.,4.,5. mjesec
3,449 patients with symptomatic acute deep vein thrombosis
3449 bolesnici sa simptomatskom akutnom dubokom venskom trombozom
3,449 patients with symptomatic acute deep vein thrombosis
3449 bolesnika sa simptomatskom akutnom dubokom venskom trombozom
3,527 (2,231 – 4,526) U/l
3527 (2231 – 4526) U/l
3-(aminomethyl)-5-methylhexanoic acid].
[(S)-3-(aminometil)-5-metilheksanoična kiselina].
3-4 mg/kg bodyweight/day
3 - 4 mg/kg tjelesne mase/danu
3-4 toxicity (%)
3 - 4 (%)
3-4 toxicity (%)
3-4 (%)
3-4) or considered
keratitis
3-6 months)
3-6 mjeseci)
3-6, 6-9 and 9-12 month study intervals, respectively.
3 do 6 mjeseci, 6 do 9 mjeseci, odnosno 9 do 12 mjeseci.
3-day regimen of aprepitant in adults
Trodnevni režim liječenja aprepitantom u odraslih
3-day treatment pack containing one 125 mg capsule and two 80 mg capsules Not all pack sizes may be marketed.
Na tržištu se ne moraju nalaziti sve veličine pakiranja.
3-day treatment pack containing: 1 x 125 mg hard capsule and
Pakiranje za trodnevno liječenje sadrži: 1 x 125 mg tvrdu kapsulu i
3-dose
3-dozno
3-dose induction regimen (weeks 0, 2, 6 or weeks 14, 16, 20 respectively) followed by maintenance therapy every 8 weeks, in combination with methotrexate.
16. i 20. tjednu), a nakon toga se provodila terapija održavanja svakih 8 tjedana, u kombinaciji s metotreksatom.
3-dose induction regimen (weeks 0, 2, 6 or weeks 14, 16, 20, respectively) followed by maintenance therapy every 8 weeks, in combination with methotrexate.
16. i 20. tjednu), a nakon toga se provodila terapija održavanja svakih 8 tjedana, u kombinaciji s metotreksatom.
3-dose primary schedule
Primarna imunizacija s 3 doze
3-methyl-(triazen-1-yl)imidazole-4-carboxamide (MTIC).
3-metil-(triazen1-il)imidazol-4-karboksamid (MTIC).
3-Minute stair climb test (stairs/minute)
3-minutni test penjanja stepenicama (stepenica/minuti)
3-month multipack containing 42 (3x14) vials of interferon beta-1b and 42 (3x14) pre-filled syringes containing solvent.
3-mjesečno višestruko pakiranje koje sadrži 42 (3x14) bočice interferona beta-1b i 42 (3x14) napunjene štrcaljke koje sadrže otapalo.
3-month multipack containing 42 (3x14) vials of interferon beta-1b and 45 (3x15) pre-filled syringes containing solvent.
3-mjesečno višestruko pakiranje koje sadrži 42 (3x14) bočice interferona beta-1b i 45 (3x15) napunjenih štrcaljki koje sadrže otapalo.
3-month multipack containing 42 (3x14) vials with powder and 42 (3x14) pre-filled syringes with solvent
3-mjesečno višestruko pakiranje koje sadrži 42 (3x14) bočice s praškom i 42 (3x14) napunjene štrcaljke s otapalom
3-month multipack containing 42 (3x14) vials with powder and 45 (3x15) pre-filled syringes with solvent
3-mjesečno višestruko pakiranje koje sadrži 42 (3x14) bočice s praškom i 45 (3x15) napunjenih štrcaljki s otapalom
3-month multipack containing 45 (3x15) vials of interferon beta-1b and 45 (3x15) pre-filled syringes containing solvent.
3-mjesečno višestruko pakiranje koje sadrži 45 (3x15) bočica interferona beta-1b i 45 (3x15) napunjenih štrcaljki koje sadrže otapalo.
3-month multipack containing 45 (3x15) vials with powder and 45 (3x15) pre-filled syringes with solvent
3-mjesečno višestruko pakiranje koje sadrži 45 (3x15) bočica s praškom i 45 (3x15) napunjenih štrcaljki s otapalom
3-month pack comprising 42 (3x14) single packs, each containing:
Tromjesečno pakiranje s 42 (3x14) pojedinačna pakiranja, svako sadrži:
3-month pack comprising 45 (3x15) single packs, each containing:
Tromjesečno pakiranje s 45 (3x15) pojedinačnih pakiranja, svako sadrži:
3-month packs comprising 3x15 single packs, each containing 1 vial with powder, 1 pre-filled syringe with solvent, 1 vial adapter with needle, 2 alcohol wipes or
pakiranje za 3 mjeseca s 3x15 pojedinačnih pakiranja od kojih svako sadrži 1 bočicu s praškom, 1 napunjenu štrcaljku s otapalom, 1 nastavak za bočicu s iglom, 2 tupfera natopljena alkoholom ili
3-O-desacyl-4’- monophosphoryl lipid A (MPL) 2 50 micrograms
3-O-desacil-4’- monofosforil lipid A (MPL) 2 50 mikrograma
3-O-desacyl-4’- monophosphoryl lipid A (MPL)2 50 micrograms
3-O-desacil-4’-monofosforil lipid A (MPL)2 50 mikrograma
3-O-desacyl-4’- monophosphoryl lipid A (MPL)3 50 micrograms
3-O-desacil-4’-monofosforil lipid A (MPL)3 50 mikrograma
3-year OS rate, % (95% CI)
3-godina stopa ukupnog 54,7 (47,7; 61,2)
3-Year PFS rateb (%) [95% CI] 23 [18, 28] 15 [10, 20]
3-godišnja stopa PFS-ab
3-yearly submission cycle
Trogodišnje podnošenje
3-yearly submission cycle
Troodišnje podnošenje
3.) Place ITLC strip in the developing chamber and allow the solvent front to migrate past the 5.4 cm mark.
3.) Postavite trakicu za ITLC u komoru za razvijanje pa pustite da fronta otapala prijeđe preko oznake od 5,4 m.
3.0 g/day
3,0 g/dan
3.0 m vs 2.6 m
3,0 m vs 2,6 m
3.0 mL (6 million IU/mL)
1,0 ml (10 milijuna IU/ml)
3.0 mL (6 million IU/mL)
3,0 ml (6 milijuna IU/ml)
3.0 ml (or 5.0 ml)
3,0 ml
3.0 ml once daily
2,5 ml jednom dnevno
3.0 ml twice daily
2,5 ml dvaput dnevno
3.0 ml twice daily
3,0 ml dva puta dnevno
3.0 ml/100 kg body weight).
3,0 ml/100 kg tjelesne mase).
3.0 ml/100 kg body weight).
3,0 ml/100 kg tjelesne težine).
3.0 ml/100 kg body weight).
3.0 ml / 100 kg tjelesne mase).
3.0 ml/100 kg body weight).
3.0 ml/ 100 kg tjelesne mase).
3.0 point worsening
pogoršanje od 3,0 boda
3.0 to 4.2
3,0 do 4,2
3.0% (95% CI =
3,0% (95% CI =
3.0a (2.6, 4.3)
3,0a (2,6; 4,3)
3.1 (2.8, NR)
3,1 (2,8; ND)
3.1% (95% CI =
3,1% (95% CI =
3.12
ombitasvir/p
3.125 μg/ml, which was the lowest concentration evaluated.
Chinese hamster ovary).
3.2 ml containing 1.60 mg fentanyl ensuring the delivery of 20 doses of 50 micrograms
3,2 ml sadrži 1,60 mg fentanila i osigurava unos 20 doza od 50 mikrograma.
3.2 ml containing 3.20 mg fentanyl ensuring the delivery of 20 doses of 100 micrograms
3,2 ml sadrži 3,20 mg fentanila i osigurava unos 20 doza od 100 mikrograma.
3.2 ml containing 6.40 mg fentanyl ensuring the delivery of 20 doses of 200 micrograms
3,2 ml sadrži 6,40 mg fentanila i osigurava unos 20 doza od 200 mikrograma.
3.2 ml solvent in a vial, 1 vial adapter
3,2 ml otapala u bočici, 1 nastavak za bočicu
3.2 ml water for injections
3,2 ml vode za injekciju
3.2-fold increase
Povećanje od 3,2
3.29B [2.27; 4.75]
3,29B [2,27; 4,75]
3.3 (P=0.0011)
3,3 (P = 0,0011)
3.3 ml once daily
2,7 ml jednom dnevno
3.3 ml once daily
3,3 ml jednom dnevno
3.3 ml twice daily
2,7 ml dvaput dnevno
3.3 ml twice daily
3,3 ml dva puta dnevno
3.3 ml twice daily
3,3 ml dvaput dnevno
3.3% versus 1.7% Grades 3-4), increased ALT (47.3% versus 37.1% all grades; 2.7% versus 2.2%
12,6% naspram 7,8%), trombocitopenija (svi stupnjevi: 47,4% naspram 33,8%; stupanj 3-4: 3,3% naspram 1,7%), povišene vrijednosti ALT-a (svi stupnjevi: 47,3% naspram 37,1%; stupanj 3-4: 2,7
3.30 to 4.90
3,30 do 4,90
3.4% (-6.0% to 12.9%)
3,4% (-6,0% do 12,9%)
3.45B [2.36;5.05]
3,45B [2,36; 5,05]
3.46 (2.08, 5.77) p = < 0.001*
3,46 (2,08; 5,77)p = < 0,001
3.46 mM
3,46 mM
3.46  2.40 hours; AUC,ss 230  67 ng. h/mL; CL/F/WT, 139  63 mL/h/kg (parameters calculated from LC-MS/MS assay results).
,ss 230  67 ngh/ml; CL/F/WT 139  63 ml/h/kg (parametri su izračunati iz rezultata LC-MS/MS metoda).
3.46  2.40 hours; AUC,ss 230  67 ng.h/mL; CL/F/WT, 139  63 mL/h/kg (parameters calculated from LC-MS/MS assay results).
,ss 230  67 ngh/ml; CL/F/WT 139  63 ml/h/kg (parametri su izračunati iz rezultata LC-MS/MS metoda).
3.5 - 7 mg/kg/day
3,5 - 7 mg/kg/dan
3.5 kg
Tjelesna
3.5 mg per dL.
3,5 mg/dl.
3.5 mg/ 3.5 ml of agalsidase alfa.
3,5 mg/ 3,5 ml agalzidaze alfa.
3.5 mg/vial 1 vial
1 bočica
3.5 ml once daily
2,7 ml jednom dnevno
3.5 ml twice daily
3,5 ml dva puta dnevno
3.5 to 10.5 mg/kg (0.035 to 0.105 ml/kg) twice daily
3,5 do 10,5 mg/kg dva puta na dan (0,035 do 0,105 ml/kg)
3.5ml twice daily
3,5ml dvaput dnevno
3.6 grams aluminium
suspenzije antacida
3.6 times the recommended treatment dose) for 6 consecutive dosing periods in young dogs was well tolerated.
3,6 puta veća doza od doze liječenja) u 6 uzastopnih doznih perioda mladi su psi dobro podnosili.
3.6 to 5.0 log10 PFU Excipient......................................................................................................................................qs 1 dose
3,6 do 5,0 log10 PFU Pomoćna tvar...............................................................................................................................qs 1 doza
3.6 to 5.0 log10 PFU* Excipients ....................................................................................................................................qs 1 dose
3,6 do 5,0 log10 PFU* Pomoćne tvari..............................................................................................................................qs 1 doza
3.6% (2.6-5.0 x ULN)
3,6% (2,6-5,0 x GGN)
3.6% (95% CI =
3,6% (95% CI =
3.61
Početni
3.7 m vs 5.9 m
3,7 m vs 5,9 m
3.7% (2 subjects)
3,7% (2 pacijenta)
3.74B [2.28; 6.13]
1,48B [0,90; 2,06]
3.75 % (w/w)
3,75% w/w
3.75 micrograms haemagglutinin/dose
3,75 mikrograma hemaglutanina/doza
3.75 micrograms haemagglutinin/dose
3,75 mikrograma hemaglutinina/doza
3.75 µg HA derived from A/Indonesia/05/2005 were administered on days 0 and 21 to 140 subjects aged 18-60 years, the anti-HA antibody responses were as follows:
0. i 21. dan kod 140 ispitanika u dobi od 18-60 godina, odgovor anti-HA protutijela bio je sljedeći:
3.78 to 5.16
3,78 do 5,16
3.8 (NR, NR)
3,8 (ND; ND)
3.8 ml once daily
3,0 ml jednom dnevno
3.8 ml once daily
3,8 ml jednom dnevno
3.8 ml twice daily
3,0 ml dvaput dnevno
3.8 ml twice daily
3,8 ml dva puta dnevno
3.8 ml twice daily
3,8 ml dvaput dnevno
3.8  2.8. Of these, 72 (89%) had Laron syndrome-like phenotype; 7 (9%) had GH gene deletion, 1 (1%) had neutralizing antibodies to GH and 1 (1%) had isolated genetic GH deficiency.
Od toga, 72(89%) imalo je fenotip sličan Laronovom sindromu; 7 (9%) imalo je deleciju gena za hormon rasta, 1 (1%) je imao antitijela koja neutraliziraju hormon rasta a 1 (1%) je imao izolirani genetski nedostatak hormona rasta.
3.9 (3.02 to 4.30)
5,4 (4,53 do 5,68)
3.9 mg pyriproxifen, 317 mg permethrin
3.9 mg piriproksifena, 317 mg permetrina
3.9% (-6.9%; -0.9%)e
23,9% (17,6%; 30,3%)f
3.94 points (SD: 1.95; 95%; CI: 2.97–4.91)
3,94 boda (SD: 1,95; 95 %; CI: 2,97–4,91)
3.98B [3.05; 5.18]
16,36B [9,05; 29,56]
3.99 to 4.78
3,99 do 4,78
3/ INSERT NEEDLE RAPIDLY PERPENDICULAR TO THE SKIN
3/ BRZIM POKRĘTOM ZABODITE IGLU OKOMITO NA KOŽU
3/13 patients did not display apparent catch-up height-gain and 1 patient did not have enough data to permit judgement.
Za 3/13 bolesnika nije se pokazao očiti zamah rasta, a za 1 bolesnika nije bilo dovoljno podataka da se omogući prosudba.
3/46 (6.5%)
≥50%a
30 - 60 min
30 – 60 min
30 - 60 min 1 mL/min
30 – 60 min
30 000 IU/0.75 ml
30000 IU/0,75 ml
30 25%; P < .0001
30 25%; P < 0,0001
30 ampoules
30 ampula
30 AMPOULES WITH 1 ML
30 AMPULA S 1 ML
30 ampoules with 1 ml.
30 ampula s 1 ml.
30 AMPOULES WITH 2 ML
30 AMPULA S 2 ML
30 April 2020
30. travnja 2020.
30 capsules
30 tvrdih kapsula
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Pošaljite upit preko našeg portala www.ema.europa.eu/contact
30 Churchill Place ● Canary Wharf ● London E14 5EU ● United Kingdom Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact
30 Churchill Place● Canary Wharf ● London E14 5EU● United Kingdom Telephone +44 (0)20 36606000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact
30 coated tablets
30 obloženih tableta
30 day (for HDPE 30’s count)
30 dana (za HDPE bočice s 30 kapsula)
30 day (for HDPE 30’s count)
30 dana (za HDPE s 30 tableta)
30 day Composite
Kompozitni za 30 dana
30 day Composite
Smrt zbog bilo kojeg uzroka
30 dispersible tablets
30 tableta za oralnu suspenziju
30 doses ELLIPTA
30 doza ELLIPTA
30 doses.
30 doza
30 dosing syringes
30 dozirnih štrcaljki
30 film-coated tablets
30 filmom obloţenih tableta
30 Film-coated tablets 30x1 Film-coated tablets
30 filmom obloženih tableta 30 x 1 filmom obloženih tableta
30 film-coated tablets 50 film-coated tablets 100 film-coated tablets
30 filmom obloženih tableta 50 filmom obloženih tableta 100 filmom obloženih tableta
30 film-coated tablets 60 film-coated tablets 120 film-coated tablets
30 filmom obloženih tableta 60 filmom obloženih tableta 120 filmom obloženih tableta
30 Film-coated tablets.
30 filmom obloženih tableta.
30 film-coated tablets: bottle
30 filmom obloženih tableta: boca
30 film-coated tablets: EU/1/12/763/001 60 film-coated tablets: EU/1/12/763/002 120 Film-coated tablets: EU/1/12/763/003
30 filmom obloženih tableta: EU/1/12/763/001 60 filmom obloženih tableta: EU/1/12/763/002 120 filmom obloženih tableta: EU/1/12/763/003